Torrens-Mas, MargalidaPerelló-Reus, Catalina MTrias-Ferrer, NeusIbargüen-González, LeslyCrespí, CatalinaGalmes-Panades, Aina MariaNavas-Enamorado, CayetanoSanchez-Polo, AndrésPierola Lopetegui, JavierMasmiquel, LluisSocias, LorenzoBarceló, CarlesGonzalez-Freire, Marta2024-10-042024-10-042022-07-22Torrens-Mas M, Perelló-Reus CM, Trias-Ferrer N, Ibargüen- González L, Crespí C, Galmes-Panades AM, et al. GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility. Front Cell Infect Microbiol. 2022 Jul 22;12:942951.http://hdl.handle.net/20.500.13003/18040https://hdl.handle.net/20.500.12105/23440Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility.enghttp://creativecommons.org/licenses/by/4.0/MutationAngiotensin-Converting Enzyme 2SARS-CoV-2HumansPeptidyl-Dipeptidase ACOVID-19Growth Differentiation Factor 15research articleAttribution 4.0 International359377031294295110.3389/fcimb.2022.9429512235-2988Frontiers in cellular and infection microbiologyopen accessPeptidil-Dipeptidasa AFactor 15 de Diferenciación de CrecimientoHumanosSARS-CoV-2Enzima Convertidora de Angiotensina 2COVID-19Mutación2-s2.0-85135551051837144000001L2018441801